MCARH171
/ BMS, Eureka Therap, Memorial Sloan-Kettering Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 04, 2025
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=20 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 ➔ Feb 2026 | Trial primary completion date: Feb 2025 ➔ Feb 2026
Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
March 04, 2024
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=20 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2024 ➔ Feb 2025 | Trial primary completion date: Feb 2024 ➔ Feb 2025
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
March 09, 2023
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=20 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2023 ➔ Feb 2024 | Trial primary completion date: Feb 2023 ➔ Feb 2024
Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
March 08, 2022
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=20 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2022 ➔ Feb 2023 | Trial primary completion date: Feb 2022 ➔ Feb 2023
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 4
Of
4
Go to page
1